By Elodie Vaz | Published on March 17, 2026 | 3 min readMyocardial
infarction is one of the leading causes of cardiovascular mortality and
disability worldwide. Even when patients survive the acute event, the
consequences for the heart can be long-lasting. The blockage of a coronary
artery deprives tissue of oxygen, leading to the death of part of the heart
muscle. In the weeks that follow, the heart attempts to repair itself, but this
healing phase often results in the formation of fibrotic tissue, which is less
functional than healthy cardiac muscle.
This
progressive remodeling weakens the organ and can ultimately lead to heart
failure. Current treatments mainly aim to limit immediate damage or stabilize
cardiac function, but they do not fully prevent this gradual decline. In this
context, a strategy designed to support the heart’s natural repair mechanisms
could transform post-infarction care.
Objective:
enhancing the heart’s natural defenses
In a
study published on March 5, 2026, in the journal Science, an
international team including researchers from Texas A&M University,
Columbia University, and the University of Oxford proposes an innovative
approach: stimulating the body’s own production of a cardioprotective hormone.
During
a myocardial infarction, the body naturally releases atrial natriuretic peptide
(ANP), a hormone capable of reducing cardiac stress and limiting long-term
damage. However, this production remains too low to significantly influence
recovery.
The
researchers’ goal is therefore to temporarily increase ANP production in order
to support the heart during the critical healing phase. “The idea is to help
the heart draw on its own healing mechanisms,” explained Dr. Ke Huang,
assistant professor at the Irma Lerma Rangel College of Pharmacy at Texas
A&M and co-author of the study, in a press release. “We are trying to offer
patients a treatment that works in harmony with the body, rather than against
it. The idea that a single injection could provide support for weeks is very
promising.”
A
methodology based on self-amplifying RNA
To
achieve this, the team developed an intramuscular injection using so-called
self-amplifying RNA (saRNA) technology. This approach is inspired by messenger
RNA platforms used in some modern vaccines, but with a key difference: the
instructions delivered to cells can temporarily replicate themselves.
In
practice, the injection provides muscle cells with transient genetic
instructions prompting them to produce ANP. Thanks to the self-amplification
mechanism, these instructions generate multiple copies of themselves over a
short period, prolonging hormone production without requiring high doses.
“This
technology gives us a more efficient way to help the body produce what it
needs, when it needs it,” said Dr. Huang. “A single dose can produce a
sustained effect, something we simply could not achieve with previous methods.”
Encouraging
results for cardiac repair
According
to the study’s findings, a single injection stimulated ANP production for
several weeks. The hormone then circulates in the bloodstream to the heart,
where it helps reduce cardiac workload and supports the repair of damaged
tissue.
“This
is essentially a reinforcement of the heart’s natural defense system,” the
researcher explained. “The body already uses ANP as a protective tool. We are
simply helping it produce enough for it to be effective during a critical
healing period.”
The
goal of this prolonged stimulation is to limit harmful scar formation, preserve
viable heart muscle, and improve cardiac function after infarction. The
researchers hope this will reduce the risk of long-term cardiovascular
complications.
This
strategy builds on the team’s previous work. In an earlier study, they
developed a microneedle patch applied directly to the heart’s surface to
deliver reparative hormones. “Our previous research with this patch identified
the NPR1 signaling pathway as one of the key drivers of beneficial
immunomodulatory effects in cardiac repair,” Dr. Huang noted. “Since ANP is the
natural ligand of the NPR1 receptor, this current study extends that work by
exploring how ANP-triggered activation leads to cardiac repair.”
The
shift from a surgical intervention to a simple injection represents a major
advance in terms of clinical feasibility.
Toward
a new therapeutic strategy?
This
approach aims to intervene during the period when the heart is most vulnerable
after an infarction. “Our goal is to protect the heart when it is most
vulnerable,” he said. “If we can reduce this initial stress and promote repair,
we may be able to alter the course of patient recovery.”
Before
any clinical application, further research will be needed to assess safety,
optimal timing of administration, and dosing, followed by clinical trials.
However,
the simplicity of a single injection could be a major advantage. “It is easy to
envision such a treatment being administered quickly and safely,” the professor
concluded. “This accessibility is what makes this work so promising. If future
studies continue to show similarly strong results, this could become a valuable
new tool in the management of heart attacks.”
In the
longer term, this strategy could pave the way for a new generation of therapies
based on the transient activation of the body’s natural repair mechanisms.
Read next: Myocardial infarction: rising in-hospital mortality, particularly among women
About the Author – Elodie Vaz
Health journalist, CFPJ graduate (2023).
Élodie explores the marks diseases leave on bodies and, more broadly, on human life. A registered nurse since 2010, she spent twelve years at patients’ bedsides before exchanging her stethoscope for a notebook. She now investigates the links between environment and health, convinced that the vitality of life cannot be reduced to that of humans alone.
